Clovis Oncology, Inc. (CLVSQ)

Market Cap	11.77M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	n/a
EPS (ttm)	-2.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,590,512
Open	0.144
Previous Close	0.156
Day's Range	0.141 - 0.159
52-Week Range	0.042 - 0.189
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2023

About CLVSQ

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal canc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 16, 2011
• Employees: 413
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLVSQ

Financial Performance

In 2021, CLVSQ's revenue was $148.76 million, a decrease of -9.58% compared to the previous year's $164.52 million. Losses were -$264.52 million, -28.35% less than in 2020.